Neurocrine Biosciences CCO Eric Benevich sells $333k in stock
Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, sold 2,154 shares of company stock worth $333,029 in a September 9, 2026 transaction. The sale was made under a pre-planned Rule 10b5-1 trading plan. Benevich executed this sale by trading 2,154 shares of Neurocrine Biosciences common stock at a price of $154.61 per share.
This was part of a trading plan Benevich established on June 10, 2026. The same day, Benevich also purchased 3,194 shares of Neurocrine Biosciences common stock through the exercise of incentive stock options, spending a total of $138,108. These options were granted on February 6, 2017, and began vesting in 48 equal monthly installments starting March 6, 2017.
After these transactions, Benevich directly owned 64,408 shares of Neurocrine Biosciences stock. Currently, Neurocrine Biosciences' stock trades at $156.57, with a market capitalization of $15.77 billion. An InvestingPro analysis indicates that Neurocrine Biosciences (NBIX) appears undervalued, placing it among the most undervalued stocks. The company's valuation is supported by a low PEG ratio of 0.22, suggesting potential for growth.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
